Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring

被引:0
作者
Yuji Kawaguchi
Jun Sawa
Yasuro Kumeda
机构
[1] Minami Osaka Hospital,Department of Internal Medicine
来源
Diabetes Therapy | 2020年 / 11卷
关键词
Glycemic variability; Hypoglycemia; Tofogliflozin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2945 / 2958
页数:13
相关论文
共 115 条
[1]  
Baena-Díez JM(2020)Standards of medical care in diabetes-2020 abridged for primary care providers Clin Diabetes 38 10-38
[2]  
Peñafiel J(2016)Risk of cause-specific death in individuals with diabetes: a competing risks analysis Diabetes Care 39 1987-1995
[3]  
Subirana I(2002)Control of post-prandial hyperglycemia—an essential part of good diabetes treatment and prevention of cardiovascular complications Nutr Metab Cardiovasc Dis 12 98-107
[4]  
Hanefeld M(2010)Severe hypoglycemia and risks of vascular events and death New Engl J Med 363 1410-1418
[5]  
Temelkova-Kurktschiev T(2004)Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up Eur J Cardiovasc Prev Rehabil 11 135-143
[6]  
Zoungas S(2011)Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study Diabetes Care 34 2237-2243
[7]  
Patel A(2020)Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2020 Diabetes Care 43 S98-S110
[8]  
Chalmers J(2014)GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract 68 557-567
[9]  
Fisman EZ(2010)Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors Postgrad Med 122 71-80
[10]  
Motro M(2016)SGLT2 inhibitors: benefit/risk balance Curr Diabetes Rep 16 92-366